These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 923986)

  • 1. The clearance of MOPC-315-tumour immunoglobulin A from the serum of BALB/c mice [proceedings].
    Jackson GD; Lemaitre-Coelho I; Vaerman JP
    Biochem Soc Trans; 1977; 5(5):1576-9. PubMed ID: 923986
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro and in vivo studies of a 2,4,6-trinitrophenyl (TNP)-binding immunoglobulin A (IgA) lymphoma isolated from MOPC-315, a TNP-binding IgA plasmacytoma of BALB/c mice.
    Gebel HM; Autry JR; Rohrer JW; Lynch RG
    J Natl Cancer Inst; 1979 Jan; 62(1):201-11. PubMed ID: 281574
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
    Kleinman R; Dray S
    Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific, immunologic regulation of differentiation of immunoglobulin expression in MOPC-315 cells during in vivo growth in diffusion chambers.
    Rohrer JW; Lynch RG
    J Immunol; 1977 Dec; 119(6):2045-53. PubMed ID: 72116
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemical properties of functional groups of mouse immunoglobulins of the IgA, IgG2a, and IgM classes.
    Kaplan H; Long BG; Young NM
    Biochemistry; 1980 Jun; 19(13):2821-7. PubMed ID: 7397107
    [No Abstract]   [Full Text] [Related]  

  • 7. Surface immunoglobulins of lymphocytes in plasmacytoma. V. The effect of RNA-rich extract from mouse plasmacytoma MOPC 104E on the immune response.
    Bhoopalam N; Chen Y; Yakulis V; Heller P
    Clin Exp Immunol; 1976 May; 24(2):357-67. PubMed ID: 1277583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of the cell dose on the development of 2 transplantable tumors in a syngeneic host].
    Pugliese A; Choc O
    G Batteriol Virol Immunol; 1976; 69(1-6):122-31. PubMed ID: 15919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of idiotype 315(Id315) and I-A antigens in MOPC-315 tumor cells grown in vivo.
    Reyero C; Burger DE; Ritacco S; Varga JM
    Cell Immunol; 1982 Nov; 73(2):290-8. PubMed ID: 6961954
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitation of total-body tumor cells (MOPC 104E). II. Ascites tumor model.
    Hiramoto RN; Ghanta VK; Hamlin NM
    J Natl Cancer Inst; 1974 Sep; 53(3):767-71. PubMed ID: 4415421
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantitation of total-body tumor cells (MOPC 104E). I. Subcutaneous tumor model.
    Ghanta VK; Hiramoto RN
    J Natl Cancer Inst; 1974 Apr; 52(4):1199-202. PubMed ID: 4826588
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic control of cross-reactive cytotoxic T-lymphocyte responses to a BALB/c tumor.
    Russell JH; Dobos CB; Graff RJ; Taylor BA
    Immunogenetics; 1981; 14(3-4):263-72. PubMed ID: 6800944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of cell-surface antigenicity of the mouse plasmacytoma. II. Lack of correlation between synthesis of myeloma protein and alteration of surface antigen.
    Ohno S; Natsu-ume-Sakai S; Migita S
    J Natl Cancer Inst; 1977 Feb; 58(2):229-37. PubMed ID: 833874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of low-dose melphalan treatment against a nonimmunogenic primary induced mouse plasmacytoma.
    Ophir R; Pick AI; Ben-Efraim S
    Anticancer Res; 1987; 7(1):91-6. PubMed ID: 3566188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discussion paper: immunosuppression induced in vivo and in vitro by different classes of plasmacytomas.
    Specter S; Friedman H
    Ann N Y Acad Sci; 1976; 276():479-87. PubMed ID: 1071972
    [No Abstract]   [Full Text] [Related]  

  • 19. Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes.
    Giovarelli M; Comoglio PM; Forni G
    Br J Cancer; 1976 Sep; 34(3):233-8. PubMed ID: 788762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of dissociation constants and ligand specificity of detergent solubilized surface membrane immunoglobulin A from MOPC-315.
    Jarvis MR; Voss EW
    Mol Immunol; 1983 Jan; 20(1):125-36. PubMed ID: 6855776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.